A003220 Stock Overview
A pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 2/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 4/6 |
Rewards
Risk Analysis
Daewon Pharmaceutical Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩16,160.00 |
52 Week High | ₩20,700.00 |
52 Week Low | ₩13,940.00 |
Beta | 0.45 |
11 Month Change | 5.35% |
3 Month Change | 6.32% |
1 Year Change | -1.46% |
33 Year Change | -7.01% |
5 Year Change | 25.01% |
Change since IPO | 254.98% |
Recent News & Updates
Does Daewon Pharmaceutical (KRX:003220) Have A Healthy Balance Sheet?
Aug 13Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) 27% Jump Shows Its Popularity With Investors
Jul 17There May Be Reason For Hope In Daewon Pharmaceutical's (KRX:003220) Disappointing Earnings
Mar 21Recent updates
Does Daewon Pharmaceutical (KRX:003220) Have A Healthy Balance Sheet?
Aug 13Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) 27% Jump Shows Its Popularity With Investors
Jul 17There May Be Reason For Hope In Daewon Pharmaceutical's (KRX:003220) Disappointing Earnings
Mar 21Does Daewon Pharmaceutical (KRX:003220) Have A Healthy Balance Sheet?
Mar 26Is Daewon Pharmaceutical Co., Ltd. (KRX:003220) A Smart Pick For Income Investors?
Mar 07Do Insiders Own Lots Of Shares In Daewon Pharmaceutical Co., Ltd. (KRX:003220)?
Feb 18Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Jan 31Did You Miss Daewon Pharmaceutical's (KRX:003220) 26% Share Price Gain?
Jan 13Here's What We Like About Daewon Pharmaceutical's (KRX:003220) Upcoming Dividend
Dec 24Daewon Pharmaceutical (KRX:003220) Seems To Use Debt Quite Sensibly
Dec 10Does Daewon Pharmaceutical Co., Ltd. (KRX:003220) Have A Place In Your Dividend Portfolio?
Nov 22Shareholder Returns
A003220 | KR Pharmaceuticals | KR Market | |
---|---|---|---|
7D | 5.6% | 14.1% | 7.9% |
1Y | -1.5% | 5.0% | -0.5% |
Return vs Industry: A003220 underperformed the KR Pharmaceuticals industry which returned 5% over the past year.
Return vs Market: A003220 matched the KR Market which returned -0.5% over the past year.
Price Volatility
A003220 volatility | |
---|---|
A003220 Average Weekly Movement | 6.6% |
Pharmaceuticals Industry Average Movement | 6.0% |
Market Average Movement | 6.4% |
10% most volatile stocks in KR Market | 11.9% |
10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A003220 has not had significant price volatility in the past 3 months.
Volatility Over Time: A003220's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1958 | 1,125 | Seung-Ryel Baek | www.daewonpharm.com |
Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company’s principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease.
Daewon Pharmaceutical Co., Ltd. Fundamentals Summary
A003220 fundamental statistics | |
---|---|
Market cap | ₩345.87b |
Earnings (TTM) | ₩23.53b |
Revenue (TTM) | ₩561.16b |
14.7x
P/E Ratio0.6x
P/S RatioIs A003220 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A003220 income statement (TTM) | |
---|---|
Revenue | ₩561.16b |
Cost of Revenue | ₩286.01b |
Gross Profit | ₩275.16b |
Other Expenses | ₩251.62b |
Earnings | ₩23.53b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 1.10k |
Gross Margin | 49.03% |
Net Profit Margin | 4.19% |
Debt/Equity Ratio | 56.9% |
How did A003220 perform over the long term?
See historical performance and comparison